Development of a novel delivery system and osteosarcoma therapy using down-regulated MSC-derived exosomes

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K09552
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56020:Orthopedics-related
• Research Institution: Hiroshima University
• Principal Investigator: Furuta Taisuke 広島大学, 病院(医), 助教 (30781645)
• Co-Investigator(Kenkyū-buntansha): 久保 忠彦 広島大学, 医系科学研究科(医), 准教授 (70397959) ; 味八木 茂 広島大学, 病院(医), 講師 (10392490) ; 安達 伸生 広島大学, 医系科学研究科(医), 教授 (30294383)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: MSC由来エクソソーム / 骨肉腫 / デリバリーシステム / homing機能

Outline of Final Research Achievements

Mesenchymal stem cells (MSCs) have been reported to have the ability to migrate (homing) to tissue lesions and malignant tumors, and the development of a delivery system to add and deliver anti-tumor effectors to target cells has attracted attention. We hypothesized that exosomes, a liquid factor released from MSCs, also have a homing function and can be delivered to target cells, and verified this hypothesis using an osteosarcoma model, showing that MSC-derived exosomes may deliver miRNA143, which has antiosteosarcoma effects, to osteosarcoma cells The results also suggest that MSC-derived exosomes may have a homing function.

Free Research Field

骨軟部腫瘍外科

Academic Significance and Societal Importance of the Research Achievements

間葉系幹細胞(Mesenchymal stem cell; 以下MSC)の組織障害・悪性腫瘍部へ遊走(homing)する機能を液性因子であるMSC由来エクソソームが有している可能性があれば、エクソソームに抗腫瘍効果因子を有するmiRNAなどを標的細胞に遊走できる可能性がある。細胞移植する必要がなければ、免疫反応による副作用のリスクも低い可能性も期待できる。悪性腫瘍治療だけでなく、他の治療にも有用な新たなデリバリーシステムになりうる可能性を秘めている。